share_log

Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings Are Actually Better Than They Appear

Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings Are Actually Better Than They Appear

Maccura BioTechnologyLtd(深圳证券交易所代码:300463)的软收益实际上比看起来要好
Simply Wall St ·  05/01 19:13

Maccura Biotechnology Co.Ltd's (SZSE:300463) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. We think that investors might be looking at some positive factors beyond the earnings numbers.

由于股价表现强劲,Maccura Biotechnology Co.td(深圳证券交易所股票代码:300463)最近的疲软利润数字似乎并没有让股东感到担忧。我们认为,除了收益数字外,投资者可能会考虑一些积极因素。

earnings-and-revenue-history
SZSE:300463 Earnings and Revenue History May 1st 2024
SZSE: 300463 收益和收入历史记录 2024 年 5 月 1 日

The Impact Of Unusual Items On Profit

不寻常物品对利润的影响

To properly understand Maccura BiotechnologyLtd's profit results, we need to consider the CN¥60m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Maccura BiotechnologyLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

为了正确了解Maccura BioTechnologyLtd的利润业绩,我们需要考虑归因于不寻常项目的6000万元支出。尽管由于不寻常项目而产生的扣除首先令人失望,但有一线希望。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。鉴于这些单列项目被认为不寻常,这并不奇怪。如果Maccura BioTechnologyLtd不认为这些不寻常的支出重演,那么在其他条件相同的情况下,我们预计其利润将在来年增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On Maccura BiotechnologyLtd's Profit Performance

我们对马库拉生物技术有限公司盈利表现的看法

Unusual items (expenses) detracted from Maccura BiotechnologyLtd's earnings over the last year, but we might see an improvement next year. Because of this, we think Maccura BiotechnologyLtd's earnings potential is at least as good as it seems, and maybe even better! On the other hand, its EPS actually shrunk in the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Maccura BiotechnologyLtd at this point in time. For example - Maccura BiotechnologyLtd has 2 warning signs we think you should be aware of.

不寻常的项目(支出)减少了Maccura BioTechnologyLtd去年的收益,但明年我们可能会看到改善。因此,我们认为Maccura BioTechnologyLtd的盈利潜力至少和看起来一样好,甚至可能更好!另一方面,其每股收益实际上在过去十二个月中萎缩了。归根结底,如果你想正确地了解公司,必须考虑的不仅仅是上述因素。因此,尽管收益质量很重要,但考虑Maccura BioTechnologyLtd目前面临的风险同样重要。例如,Maccura BioTechnologyLtd 有两个警告信号,我们认为你应该注意。

This note has only looked at a single factor that sheds light on the nature of Maccura BiotechnologyLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

这份报告只研究了揭示Maccura BioTechnologyLtd利润性质的单一因素。但是,还有很多其他方法可以让你对公司的看法。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发